Managing Physicians, Managing Prescriptions
Executive SummaryThere was a time when managed care tried to control drug spending through strategies that compromised physician prerogative. But growing consumerism and the healthy US economy has led to questioning of managed care practices. New physician-driven organizations are looking at drug costs as part of a broader disease management agenda, while PBMs are taking a more doctor-friendly approach.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.